>>Signaling Pathways>> Others>>Antitumor Compound 1

Antitumor Compound 1

Catalog No.GC35363

항종양 화합물 1은 활성 성분으로서 우수한 항종양 활성을 갖는 신규 이미다조피리딘을 포함하는 강력한 화합물이다.

Products are for research use only. Not for human use. We do not sell to patients.

Antitumor Compound 1 Chemical Structure

Cas No.: 420126-30-3

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$306.00
재고 있음
2mg
US$216.00
재고 있음
5mg
US$324.00
재고 있음
10mg
US$464.00
재고 있음
50mg
US$1,391.00
재고 있음
100mg
US$1,947.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Antitumor Compound 1 is a potent compound which comprises a new imidazopyridine having excellent antitumor activity as an active ingredient.Reference:Polymer-linked imidazopyridines useful as tumor-targeting cytotoxic agentsBy Kasuya, Hiroshi; Miyazaki, Hideki; Hayakawa, Ichio; Kanno, Yuichi; Watanabe, KazuyoshiFrom Jpn. Kokai Tokkyo Koho (2004), JP 2004002826 A 20040108. Pharmaceuticals containing imidazopyridines for prophylactic and therapeutic treatment of tumorBy Hayakawa, Ichio; Kanno, Yuichi; Azuma, Toshiki; Furukawa, Hidehiko; Naruto, Shunji; Kurakata, ShinichiFrom Jpn. Kokai Tokkyo Koho (2003), JP 2003313126A 20031106.Preparation of imidazopyridine derivatives as antitumor agentsBy Hayakawa, Ichiro; Sugano, Yuichi; Agatsuma, Toshinori; Furukawa, Hidehiko; Kurakata, Shinichi; Naruto, ShunjiFrom PCT Int. Appl. (2002), WO 2002034748 A1 20020502.

리뷰

Review for Antitumor Compound 1

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Antitumor Compound 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.